This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Early Registration Savings Deadline Expires In

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Richard Rogers, Ph.D.
Principal Scientist at Bristol Myers Squibb, USA


Dr. Rogers got his Ph.D. from the Johns Hopkins University in 2003.  In Mike Matunis’ lab he studied the effects of Sumo modification on transcription factors.  As a post doc, Dr. Rogers joined John Aitchison’s lab at the Institute for Systems Biology.  At the ISB, Dr. Rogers expanded his research on post translational modification by applying mass spectrometry to detect phosphoryatlation and other ubiquitin-like modifications in macrophages.  In 2012, Dr. Rogers joined the Analytical Sciences group at Amgen.  At Amgen, Dr. Rogers developed a mass spectrometry based multi-attribute method (MAM) for biotherapeutic characterization and release from QC.  Dr. Rogers is currently working for Just Biotherapeutics in Seattle.  At Just, Dr. Rogers is continuing his work on the MAM.

Agenda Sessions

  • Investigating Analytical Challenges for Cell & Gene Therapies